Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and tofacitinib

lestaurtinib has been researched along with tofacitinib in 4 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(tofacitinib)		Trials
(tofacitinib)		Recent Studies (post-2010) (tofacitinib)
12412631,6192141,519

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)tofacitinib (IC50)
Chain A, Tyrosine-protein kinaseHomo sapiens (human)0.0117
Chain A, Tyrosine-protein kinaseHomo sapiens (human)0.0117
Chain A, Tyrosine-protein kinase JAK2Homo sapiens (human)0.0117
Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)0.0815
Tyrosine-protein kinase JAK2Homo sapiens (human)0.2065
Rho-associated protein kinase 2Homo sapiens (human)3.4
Epidermal growth factor receptorHomo sapiens (human)0.0815
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0815
Tyrosine-protein kinase LckHomo sapiens (human)2.6933
Cytochrome P450 3A4Homo sapiens (human)0.015
Cytochrome P450 2C8Homo sapiens (human)0.0014
Cytochrome P450 2D6Homo sapiens (human)0.0037
Cytochrome P450 2A6Homo sapiens (human)0.012
Tyrosine-protein kinase JAK1Homo sapiens (human)0.0575
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)0.1411
Cytochrome P450 2C19Homo sapiens (human)0.0016
Tyrosine-protein kinase TecHomo sapiens (human)0.0815
Tyrosine-protein kinase TXKHomo sapiens (human)0.0815
Tyrosine-protein kinase BlkHomo sapiens (human)0.0815
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)0.0815
Tyrosine-protein kinase JAK3Homo sapiens (human)0.0408
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.0006
Tyrosine-protein kinase BTKHomo sapiens (human)0.0815
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)0.0815
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.0815
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)0.0143
Tyrosine-protein kinase JAK3Mus musculus (house mouse)0.664
Tyrosine-protein kinase JAK2Rattus norvegicus (Norway rat)3.57
Tyrosine-protein kinase JAK3Rattus norvegicus (Norway rat)1.2
Serine/threonine-protein kinase TBK1Homo sapiens (human)5.76

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Abbasian, M; Cathers, B; Chamberlain, P; Delker, S; Jackson, P; Mahmoudi, A; Muir, J; Pagarigan, B; Raheja, N1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1

Other Studies

4 other study(ies) available for lestaurtinib and tofacitinib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Apoenzymes; Carbazoles; Crystallography, X-Ray; Furans; Humans; Ligands; Piperidines; Protein Conformation; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Pyrroles

2014
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022